Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer

被引:27
作者
Mustea, A. [1 ]
Pirvulescu, C. [1 ]
Koensgen, D. [1 ]
Braicu, E. I. [2 ]
Yuan, S. [3 ]
Sun, P.
Lichtenegger, W. [1 ]
Sehouli, J. [1 ]
机构
[1] Charite Univ Med Berlin, Dept Obstet & Gynecol, D-13353 Berlin, Germany
[2] Med Univ, Dept Obstet & Gynecol, Cluj Napoca, Romania
[3] Zhejiang Canc Hosp, Dept Gynecooncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
IL-1; cytokine; expression; ascites; survival; ovarian cancer;
D O I
10.1016/j.cyto.2008.01.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Cytokines play a major role in promoting the growth and metastatic spread of cancer cells. Interleukin-1 alpha and beta(IL-1) and IL-1 RA are known to be critically involved in carcinogenesis and in various solid tumors. There are limited data on expression of IL-1 alpha, 0 and RA in serum and ascites in patients with advanced ovarian cancer. Objectives of this study were to investigate the level of IL-1 alpha, IL-1 beta and IL-1 RA in serum and ascites from patients with ovarian cancer and their impact on the prognosis. Methods: Fifty-three women with ovarian cancer (OC) (33 patients with primary OC and 20 with relapsed OC) and 50 women with benign gynaecological diseases as a control group (CG) were enrolled onto this prospective study. IL-1 alpha, beta and RA levels were analyzed in serum and ascites by ELISA technique. Results: The median age was 55 years (range 19 - 80) in the ovarian cancer group and 40 years (range 15 - 89) in the controls. The distribution of histological type of ovarian cancer was as follows: serous-papillary 43 (81.1%), 4 (7.5%) mucinous, 3 (5.7%) endometroid and 3 (5.7%) clear cell carcinoma. The concentrations of IL-1 beta and RA in ascites or peritoneal fluid were significantly increased in patients with OC in comparison to the CG, for both cytokines (p < 0.0001); also the concentration of IL-1 RA in serum was increased in OC (p=0.003) vs. CG. An increased level of IL-1 beta in ascites correlated significantly with a poorer histopathological grading (p=0.038). IL-1 RA concentration in ascites was correlated with advanced FIGO stage (p=0.049) and the IL-1 RA serum level with ascites volume (<= 500 ml vs. > 500 ml) (p=0.046). Patients with IL-1 RA level in ascites lower than the cut off value of 695.6 pg/ml showed a significant better progression-free median survival (24.6 vs. 12.8 months, p = 0.008) and postoperative median overall survival (34.6 vs. 17 months, p=0.01) in comparison to patients with an IL-1 RA level in ascites higher than the cut off level. Additionally, a higher expression of IL- I P in serum (p=0.004) and ascites (p=0.05) reduced significantly the progression-free survival. In the multivariate analysis, expression of IL-1 RA in ascites was an independent prognostic factor for good progression-free and postoperative overall survival (HR, 0.39 95% CI, 0. 18 - 0.83, p=0.01, HR, 0.36 95% CL 0. 16 - 0.8, p=0.01). Conclusions: IL- I RA levels in ascites lower than the cut off value of 695.6 pg/ml are associated with a significant improvement in postoperative and progression-free survival. IL-1 RA shows a prognostic relevance in ovarian cancer. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 43 条
[11]  
Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005
[12]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[13]  
DIRK E, 2000, J BIOL CHEM, V275, P1169
[14]   INTERLEUKIN-1 RECEPTOR ANTAGONIST IS A MEMBER OF THE INTERLEUKIN-1 GENE FAMILY - EVOLUTION OF A CYTOKINE CONTROL MECHANISM [J].
EISENBERG, SP ;
BREWER, MT ;
VERDERBER, E ;
HEIMDAL, P ;
BRANDHUBER, BJ ;
THOMPSON, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5232-5236
[15]   Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial [J].
Fleischmann, RM ;
Schechtman, J ;
Bennett, R ;
Handel, ML ;
Burmester, GR ;
Tesser, J ;
Modafferi, D ;
Poulakos, J ;
Sun, G .
ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :927-934
[16]   Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma [J].
Fujiwaki, R ;
Iida, K ;
Nakayama, K ;
Kanasaki, H ;
Hata, K ;
Katabuchi, H ;
Okamura, H ;
Miyazaki, K .
GYNECOLOGIC ONCOLOGY, 2003, 89 (01) :77-83
[17]   Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers [J].
Fujiwaki, R ;
Hata, T ;
Miyazaki, K ;
Kawamura, T ;
Inada, K .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (12) :1407-1408
[18]   Interleukin-1α concentration in tumors as a risk factor for liver metastasis in gastric cancer [J].
Furuya, Y ;
Ichikura, T ;
Mochizuki, H .
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1999, 29 (03) :288-289
[19]  
Glaccum MB, 1997, J IMMUNOL, V159, P3364
[20]   Transforming growth factor-β1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells [J].
Hirashima, Y ;
Kobayashi, H ;
Suzuki, M ;
Tanaka, Y ;
Kanayama, N ;
Terao, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (29) :26793-26802